LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Inclusion Criteria: * Age \> 18 years old * Recipient of a double pulmonary allograft at least 12 months before study entry * Subjects with clinically diagnosed CLAD-BOS phenotype (all 3 required) * BOS defined as screening FEV1 between 85-51% of the baseline as defined by the 2 highest FEV1 measures at least 3 weeks apart. * Diagnosis within 12 months of screening visit. * FEV1 decline is persistent as defined by decline sustained for \> 30 days. * Currently receiving Standard Immunosuppression. This is defined as a combination of 3 medications including Prednisone, Mycophenolate or Azathioprine, and Tacrolimus or Cyclosporine. The dosing should be stable for 4 weeks prior to screening. * Absence of oral sirolimus or everolimus treatment for at least 4 weeks prior to screening based on the half-life and resolution of the tissue effects * Stable enough to enable routine post-transplant bronchoscopy with BAL and biopsy when indicated * Capable of understanding the purposes and risks of the study * Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. * Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry * Women of childbearing potential if sexually active must agree to using highly effective contraception during study and for 90 days after discontinuation of study treatment * Women of chil…